sever
acut
respiratori
syndrom
sar
infecti
diseas
caus
newli
identifi
human
coronaviru
sarscov
current
effect
drug
exist
treat
sarscov
infect
studi
investig
whether
panel
commerci
avail
antivir
drug
exhibit
vitro
antisarscov
activ
drugscreen
assay
score
virusinduc
cytopath
effect
cultur
cell
use
test
clinic
approv
compound
sever
major
antivir
pharmacolog
class
nucleosid
analog
interferon
proteas
inhibitor
revers
transcriptas
inhibitor
neuraminidas
inhibitor
complet
inhibit
cytopath
effect
sarscov
cultur
observ
interferon
subtyp
human
leukocyt
interferon
find
support
clinic
test
approv
interferon
treatment
sar
ever
acut
respiratori
syndrom
sar
infecti
diseas
caus
newli
identifi
human
coronaviru
sarscov
diseas
produc
sever
pneumonia
report
fatal
outcom
current
effect
drug
exist
treat
sarscov
infect
urgenc
outbreak
led
empir
use
broadspectrum
antibiot
antivir
agent
affect
patient
sever
countri
intens
effort
way
gain
insight
mechan
viral
replic
order
develop
target
antivir
therapi
vaccin
develop
effect
safe
vaccin
chemotherapeut
agent
sar
cov
howev
may
take
year
recent
epidem
shown
knowledg
lack
regard
clinic
manag
treatment
infect
patient
ribavirin
oseltamivir
foscarnet
intraven
immunoglobulin
agent
use
treat
patient
preliminari
result
vitro
test
indic
ribavirin
concentr
inhibit
virus
sensit
ribavirin
inhibit
replic
celltocel
spread
sarscov
howev
us
center
diseas
control
prevent
conclud
vitro
test
antivir
drug
coronaviru
isol
inform
clinic
outcom
patient
treat
ribavirin
antivir
drug
control
trial
need
aim
studi
investig
whether
panel
current
avail
antivir
agent
exhibit
vitro
antisarscov
activ
three
gener
antivir
strategi
gener
found
direct
antivir
effect
inhibit
viral
entri
replic
cellular
level
target
virusrel
process
enhanc
host
immun
respons
total
drug
approv
clinic
use
treatment
viral
infect
test
studi
repres
compound
major
antivir
pharmacolog
class
current
commerci
avail
nucleosid
analog
interferon
proteas
inhibitor
revers
transcriptas
inhibitor
neuraminidas
inhibitor
cellbas
assay
util
cytopath
endpoint
cpe
set
use
vero
cell
screen
antivir
compound
sarscov
shown
infect
vero
cell
african
green
monkey
kidney
cell
line
remain
vitro
model
sarscov
infect
initi
screen
follow
plaqu
reduct
assay
determin
effect
concentr
ec
compound
show
posit
result
experi
allow
rapid
screen
commerci
avail
antivir
agent
enabl
vitro
evid
activ
move
expediti
clinic
studi
sinc
safeti
pharmacokinet
inform
human
alreadi
avail
diseas
indic
report
certain
interferon
subtyp
exhibit
vitro
inhibitori
activ
sarscov
candid
followup
studi
anim
model
patient
determin
efficaci
vivo
rapidli
identifi
pharmacolog
agent
could
use
treat
sar
collect
antivir
drug
test
sarscov
etiolog
agent
atyp
pneumonia
investig
wide
spectrum
potenti
molecular
target
decid
cover
entir
pharmacolog
rang
commerci
avail
antivir
agent
includ
agent
expect
activ
coronavirus
inform
antivir
drug
provid
obtain
prescrib
inform
sheet
commun
manufactur
nucleosid
analogu
divers
class
compound
gener
inhibit
viral
rna
dna
polymeras
enzym
interf
nucleic
acid
synthesi
studi
select
compound
target
dna
virus
herp
simplex
viru
hsv
varicellazost
virus
vzv
acyclovir
ganciclovir
foscarnet
ribavirin
activ
rang
dna
rna
virus
differ
cell
line
ed
rang
antiretrovir
hiv
drug
includ
revers
transcriptas
rt
inhibitor
proteas
inhibitor
select
hiv
nucleosid
rt
inhibitor
studi
zidovudin
lamivudin
hiv
proteas
inhibitor
studi
indinavir
nelfinavir
saquinavir
third
group
antivir
studi
neuraminidas
inhibitor
commerci
avail
prepar
zanamivir
oseltamivir
use
studi
interferon
next
major
class
antivir
studi
variou
subtyp
interferon
human
leukocyt
use
amantadin
old
antivir
compound
also
studi
differ
term
use
express
antivir
activ
name
ec
effect
concentr
ec
inhibitori
concentr
ic
tabl
illustr
rang
activ
select
virus
tenfold
dilut
drug
test
cover
broad
rang
concentr
inhibitori
dosag
report
manufactur
viralhost
combin
compound
alreadi
present
aqueou
inject
made
volum
use
hank
buffer
salin
solut
tablet
capsul
formul
solubl
activ
ingredi
outer
coat
remov
wherev
applic
prepar
ground
mortar
pestl
content
dissolv
water
vortex
centrifug
thereaft
g
requir
volum
pipet
supernat
dilut
accordingli
activ
ingredi
insolubl
water
nelfinavir
saquinavir
content
dissolv
dimethylsulphoxid
dmso
care
taken
ensur
final
concentr
dmso
dilut
would
exceed
plaqu
assay
fivefold
drug
dilut
prepar
use
growth
media
specifi
vero
cell
american
type
cultur
collect
manassa
va
propag
cm
cell
cultur
flask
growth
medium
consist
medium
sigma
st
loui
mo
supplement
fetal
calf
serum
fc
biolog
industri
kibbutz
beit
haemek
israel
sarscov
isol
sar
patient
singapor
previous
sequenc
propag
vero
cell
briefli
ml
stock
viru
ad
confluent
monolay
vero
cell
incub
co
h
ml
medium
supplement
fc
ad
cultur
incub
co
supernat
harvest
h
cultur
inhibit
cpe
well
observ
invert
microscop
supernat
clarifi
rpm
divid
aliquot
place
cryovial
store
use
viru
cultur
assay
carri
biosafeti
laboratori
environment
health
institut
accord
condit
set
biosafeti
microbiolog
biomed
laboratori
viru
titer
frozen
cultur
supernat
determin
use
plaqu
assay
briefli
viru
serial
dilut
ad
duplic
monolay
vero
cell
plate
h
incub
co
viral
inoculum
aspir
ml
carboxymethylcellulos
overlay
medium
supplement
fc
ad
well
day
incub
cell
fix
formalin
stain
crystal
violet
plaqu
count
visual
viru
titer
plaqueform
unit
per
ml
pfuml
calcul
protocol
use
adapt
aljabri
et
al
drug
test
quadrupl
briefli
serial
dilut
drug
incub
vero
cell
give
final
cell
count
cell
per
well
plate
incub
period
h
co
except
interferon
incub
overnight
cell
ten
microlit
viru
concentr
pfuwel
ad
test
well
plate
incub
co
day
observ
daili
cpe
end
point
drug
dilut
inhibit
cpe
cia
quadrupl
well
determin
cytotox
serial
dilut
drug
incub
vero
cell
give
final
cell
count
cell
per
well
plate
without
viral
challeng
plate
incub
co
day
examin
toxic
effect
use
invert
microscop
trypsin
vero
cell
resuspend
growth
medium
preincub
interferon
serial
fivefold
dilut
quadrupl
well
plate
next
day
medium
aspir
viru
ad
well
titer
pfuwel
incub
h
viru
inoculum
aspir
carboxymethylcellulos
overlay
contain
mainten
medium
appropri
interferon
concentr
ad
day
incub
plate
fix
stain
describ
previous
number
plaqu
count
visual
concentr
drug
inhibit
plaqu
well
ic
determin
result
plot
microsoft
excel
polynomi
order
three
use
approxim
data
extrapol
ic
ic
valu
high
titer
infecti
sarscov
origin
deriv
respiratori
sampl
sar
patient
propag
vero
cell
cpe
sarscov
vero
evid
within
hour
infect
figur
sarscovinfect
cell
display
cpe
character
appear
round
cell
destruct
monolay
collect
antivir
drug
test
sarscov
cpe
inhibit
assay
tabl
set
drug
test
includ
seven
interferon
five
nucleosid
analog
three
proteas
inhibitor
two
rt
inhibitor
two
neuraminidas
inhibitor
complet
inhibit
cpe
observ
four
seven
interferon
initi
screen
high
viral
challeng
pfuwel
high
multipl
infect
moi
rate
use
complet
inhibit
express
cia
observ
interferon
betaferon
iuml
interferon
alferon
iuml
interferon
wellferon
iuml
human
leukocyt
interferon
multiferon
iuml
ribavirin
also
complet
inhibit
cpe
tabl
none
drug
show
complet
inhibit
cpe
even
highest
concentr
drug
test
tabl
rebif
show
slight
inhibit
cpe
iuml
inhibit
complet
screen
viru
load
pfuwel
likewis
roferon
show
slight
incomplet
inhibit
iuml
criteria
ascertain
antisarscov
activ
screen
set
inhibit
cpe
high
dose
interferon
may
result
sever
clinic
side
effect
chose
conduct
evalu
interferon
show
complet
inhibit
initi
screen
name
wellferon
multiferon
betaferon
alferon
base
upon
result
primari
screen
four
activ
interferon
ribavirin
retest
two
lower
viral
challeng
pfu
well
four
drug
show
inhibitori
effect
although
cia
depend
viral
load
tabl
lowest
viral
load
cia
iuml
interferon
betaferon
human
leukocyt
interferon
multiferon
iuml
interferon
alferon
interferon
wellferon
respect
cytotox
interferon
observ
near
inhibitori
concentr
ribavirin
show
inhibitori
activ
three
viral
load
high
concentr
drug
mgml
high
concentr
ribavirin
mgml
cytotox
effect
observ
cell
report
cell
type
consid
ribavirin
inact
sarscov
plaqu
reduct
assay
format
pfu
sarscov
moi
conduct
determin
ic
betaferon
alferon
multiferon
three
compound
show
greatest
potenc
inhibit
cpe
addit
suppli
avail
test
interferon
wellferon
product
drug
discontinu
cell
preincub
h
fivefold
dilut
drug
viralinduc
plaqu
develop
day
count
determin
inhibitori
effect
drug
variou
concentr
three
interferon
prepar
display
dosedepend
inhibit
sarscov
plaqu
format
assay
figur
ic
ic
determin
iuml
betaferon
iuml
alferon
iuml
multiferon
betaferon
alferon
multiferon
wellferon
ribavirin
inhibit
cpe
sarscovinfect
vero
cell
decreas
order
potenc
ribavirin
drug
wide
use
initi
effort
manag
sar
infect
inhibit
cpe
complet
viru
load
pfu
per
well
concentr
rang
observ
much
higher
concentr
inhibit
virus
respiratori
syncyti
viru
ed
hiv
resist
strain
rhinoviru
includ
virus
test
vero
cell
west
nile
viru
new
york
isol
uganda
isol
addit
cpe
observ
slight
cytotox
microscop
examin
cell
make
difficult
accur
obtain
vitro
efficaci
data
sarscov
appear
due
low
activ
ribavirin
vitro
inhibitori
dose
may
achiev
clinic
possibl
ribavirin
would
effect
combin
interferon
combin
therapi
ribavirin
interferon
becom
standard
treatment
chronic
hepat
c
addit
test
effect
ribavirin
betaferon
combin
rang
concentr
ribavirin
rang
concentr
betaferon
iuml
pfu
combin
demonstr
observ
synergist
inhibitori
effect
sarscov
studi
describ
vitro
activ
four
interferon
subtyp
sarscov
interferon
use
anticanc
antivir
agent
particular
treat
hepat
b
c
infect
variou
group
report
clinic
benefit
intranas
administ
interferon
human
volunt
inocul
nonsar
coronavirus
antivir
activ
interferon
mediat
direct
effect
infect
cell
modul
immun
respons
interferon
interact
specif
surfac
cell
receptor
lead
product
interferonstimul
gene
product
synthas
protein
kinas
pkr
sarscov
infect
conveni
start
point
use
interferon
sarscov
infect
would
usual
clinic
dose
treatment
hepat
b
c
common
clinic
dosag
interferon
rang
million
iu
three
time
week
million
iu
daili
interferon
data
regard
efficaci
treatment
hepat
c
conflict
interferon
dose
million
iu
three
time
weekli
usual
use
treatment
infect
patient
whose
condit
longer
respond
therapi
plasma
level
interferon
administ
subcutan
rout
usual
low
correspondingli
short
halfliv
view
mechan
action
absolut
serum
level
may
meaning
measur
biolog
activ
interferon
compar
induct
cellular
product
oligoadenyl
synthas
interferon
activ
vari
among
differ
cell
type
howev
specif
interferon
subtyp
inhibit
sarscov
vero
cell
may
necessarili
effect
cell
convers
may
also
truethat
drug
neg
vero
cell
may
effect
cell
type
current
identifi
vitro
model
sarscov
infect
enabl
us
address
celltyp
specif
drug
effect
also
interferon
subtyp
exhibit
differ
activ
sarscov
studi
mechan
differ
activ
unknown
among
product
test
sourc
interferon
amount
glycosyl
differ
prepar
deriv
human
lymphoblastoid
leukocyt
cell
other
recombinantli
produc
escherichia
coli
mammalian
cell
cultur
know
import
observ
respect
possibl
antivir
mechan
interferon
sarscov
potenti
clinic
implic
differ
studi
describ
rapid
screen
commerci
avail
compound
extens
vivo
research
evid
activ
data
vitro
studi
howev
easili
correl
clinic
perform
rather
present
promis
candid
followup
studi
definit
recommend
antisarscov
activ
compound
human
made
vivo
set
conclus
interferon
human
leukocyt
interferon
exhibit
antivir
activ
